Skip to main content

DavidChungMDPhD

Oncology New York, NY

Hematologic Oncology

Director, Clinical Research and Section Chief, Multiple Myeloma, Northwell Health Cancer Institute

Overview of Dr. Chung

David Chung, MD, based in New York, is a specialist in Oncology with a subspecialty in Hematologic Oncology. His education includes a residency in Internal Medicine at UCLA David Geffen School of Medicine/UCLA Medical Center from 2001-2004, a fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center from 2004-2008, and a medical degree from Georgetown University School of Medicine (Class of 2001). Dr. Chung has expertise in immunotherapy, hematologic oncology, bone marrow transplantation, plasma cell myeloma, and multiple myeloma. He has published extensively in the field and has been involved in multiple clinical trials. Dr. Chung's notable contributions have been recognized with numerous awards, including the Myeloma Crowd Research Award and the Clinical Investigation Award from Experimental Therapeutics Center, MSKCC, among others.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2008
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2001 - 2004
  • Georgetown University School of Medicine
    Georgetown University School of MedicineClass of 2001

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2002 - Present
  • FL State Medical License
    FL State Medical License 2021 - Present
  • CT State Medical License
    CT State Medical License 2023 - 2025
  • NJ State Medical License
    NJ State Medical License 2020 - 2025
  • NY State Medical License
    NY State Medical License 2004 - 2025
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Myeloma Crowd Research Award Myeloma Crowd Foundation, 2018
  • Clinical Investigation Award Experimental Therapeutics Center, MSKCC, 2014
  • Translational New Investigator Award Department of Defense, 2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
    David J. Chung, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
    David J. Chung, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
    David J. Chung, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma... 
    2021 ASH Annual Meeting - 12/13/2021
  • Evaluation of Tumor Vaccine Generation in a Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant (AutoHCT) Followed By Lenalidomide Maintenanc... 
    2020 Transplantation & Cellular Therapy Meetings, Orlando, FL - 2/2020
  • Stem Cell Mobilization and Autograft Purity with Novel Induction Regimens in Multiple Myeloma 
    17th International Myeloma Workshop, Boston, MA - 10/2019
  • Join now to see all

Press Mentions

  • Potential New Approach to Enhancing Stem-Cell Transplants
    Potential New Approach to Enhancing Stem-Cell TransplantsAugust 8th, 2024

Professional Memberships